Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12607000602426
Ethics application status
Approved
Date submitted
20/10/2007
Date registered
22/11/2007
Date last updated
4/02/2009
Type of registration
Retrospectively registered
Titles & IDs
Public title
Bronchoscopic Vapour Therapy for Emphysema
Query!
Scientific title
A First-in-Man Safety & Feasibility Study of Bronchoscopic Thermal Vapour Ablation (BTVA) for Lung Volume Reduction in Patients with Heterogeneous Upper Lobe Emphysema (Phase 1)
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Emphysema
2486
0
Query!
Condition category
Condition code
Respiratory
2586
2586
0
0
Query!
Chronic obstructive pulmonary disease
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Vapour (steam) is infused into a targeted emphysematous lung segment for approximately 4-8 seconds. No more than 3 segments within 1 lobe of a lung will be treated. The 3 segments will be treated in one procedure, with a waiting time of at least 4 minutes between each vapour treatment. The total time of the BTVA procedure is expected to be 1.5 hours.
Query!
Intervention code [1]
2216
0
Treatment: Devices
Query!
Comparator / control treatment
Not Applicable - single group trial
Query!
Control group
Uncontrolled
Query!
Outcomes
Primary outcome [1]
3496
0
All serious and non-serious events secondary to the BTVA procedure
Query!
Assessment method [1]
3496
0
Query!
Timepoint [1]
3496
0
Initiation through 6 months after intervention
Query!
Secondary outcome [1]
5832
0
Pulmonary Function Status as measured by Forced Expiratory Volume in 1 second (FEV1) and Diffusing Capacity of Lung - carbon monoxide (DLCO).
Query!
Assessment method [1]
5832
0
Query!
Timepoint [1]
5832
0
3 and 6 months after intervention
Query!
Secondary outcome [2]
5833
0
Exercise capacity (6 minute walk test)
Query!
Assessment method [2]
5833
0
Query!
Timepoint [2]
5833
0
3 and 6 months after intervention
Query!
Secondary outcome [3]
5834
0
Quality of Life (St. George Respiratory Questionnaire)
Query!
Assessment method [3]
5834
0
Query!
Timepoint [3]
5834
0
3 and 6 months after intervention
Query!
Eligibility
Key inclusion criteria
Patients diagnosed with heterogeneous emphysema with upper lobe predominance as evidence by Computed Tomography (CT) imaging
FEV1 > 45% predicted; Total Lung Capacity (TLC) / 100% predicted; Residual Volume (RV) > 150% predicted
Exercise Capacity: Ability to walk > 140 metres in 6 minutes after completing a pulmonary rehabilitation program
Non-smoking for 4 months prior to study enrollment
Dyspnea scoring > or = 2 (of 4)
Query!
Minimum age
40
Years
Query!
Query!
Maximum age
80
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Patients diagnosed with homogeneous emphysema or heterogeneous emphysema with lower lobe predominance
Known alpha-1 antityrpsin deficiency
Body Mass Index (BMI) < 15kg/m2 or > 35 kg/m2 - body mass index is the relationship between weight and height that is associated with body fat and health risk
Clinically significant asthma, chronic bronchitis or bronchiectasis
Patients with heart/lung transplant or prior lung volume reduction surgery
Patients with significant pulmonary hypertension, heart disease or history of stroke
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Date of first participant enrolment
Anticipated
22/10/2007
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
10
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment postcode(s) [1]
302
0
4032
Query!
Recruitment postcode(s) [2]
303
0
3181
Query!
Recruitment postcode(s) [3]
304
0
5000
Query!
Funding & Sponsors
Funding source category [1]
2741
0
Commercial sector/Industry
Query!
Name [1]
2741
0
Uptake Medical Corp
Query!
Address [1]
2741
0
1942 1st Avenue
3rd FL
Seattle Washinton 98101
Query!
Country [1]
2741
0
United States of America
Query!
Primary sponsor type
Commercial sector/Industry
Query!
Name
Uptake Medical Corp.
Query!
Address
1942 1st Avenue
3rd FL
Seattle Washinton 98101
Query!
Country
United States of America
Query!
Secondary sponsor category [1]
2476
0
Other
Query!
Name [1]
2476
0
Novotech (Australia) Pty Limited
Query!
Address [1]
2476
0
Level 3
19 Harris Street
Pyrmont NSW 2009
Query!
Country [1]
2476
0
Australia
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
4658
0
The Prince Charles Hospital
Query!
Ethics committee address [1]
4658
0
Human Research Ethics Committee
The Prince Charles Hospital
Northside Health Service District
Rode Road
Chermside QLD 4032
Query!
Ethics committee country [1]
4658
0
Australia
Query!
Date submitted for ethics approval [1]
4658
0
31/08/2007
Query!
Approval date [1]
4658
0
14/09/2007
Query!
Ethics approval number [1]
4658
0
EC2787
Query!
Ethics committee name [2]
4742
0
The Alfred Hospital
Query!
Ethics committee address [2]
4742
0
The Alfred Hospital Ethics Committee Office
Commercial Road
Melbourne Victoria 3004
Query!
Ethics committee country [2]
4742
0
Australia
Query!
Date submitted for ethics approval [2]
4742
0
17/09/2007
Query!
Approval date [2]
4742
0
12/11/2007
Query!
Ethics approval number [2]
4742
0
ABN 27 318 956 319
Query!
Summary
Brief summary
The primary purpose of this study is to established the side effect and benefit profile of BTVA in patients with heterogeneous upper lobe emphysema. The results will help to support subsequent clinical trials in a larger patient sample.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
28135
0
Query!
Address
28135
0
Query!
Country
28135
0
Query!
Phone
28135
0
Query!
Fax
28135
0
Query!
Email
28135
0
Query!
Contact person for public queries
Name
11292
0
Pamela P. Simons, BS, RT(r)
Query!
Address
11292
0
Vice-President
Clinical & Regulatory Affairs
Clinical & Regulatory Affairs Office
Uptake Medical Corp.
9688 63rd Avenue
Maple Grove
Minnesota 55369
Query!
Country
11292
0
United States of America
Query!
Phone
11292
0
+1 612 5641612
Query!
Fax
11292
0
+1 763 5365949
Query!
Email
11292
0
[email protected]
Query!
Contact person for scientific queries
Name
2220
0
Peter Hopkins, MD, MBBS, FRACP
Query!
Address
2220
0
Consultant Tranplant & Thoracic Physician
Prince Charles Hospital
Private Practice Clinic
Rode Road
Chermisde QLD 4032
Query!
Country
2220
0
Australia
Query!
Phone
2220
0
+61 7 31396486
Query!
Fax
2220
0
Query!
Email
2220
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF